FDA military informed consent rule back to drawing board
Executive Summary
FDA withdraws its final rule on determining the circumstances under which informed consent can be waived for troops being given investigational drugs in combat situations. The rule would finalize a 1999 1interim final rule, which specifies that the President, and not the FDA commissioner, can make the determination (2"The Pink Sheet" Nov. 29, 1999, p. 10). FDA pulled the rule Oct. 10 after submitting it to OMB July 21...
You may also be interested in...
DoD Investigational Drug Testing Policy Expected By Early Next Year
The Department of Defense will develop a protocol on the use of investigational drugs on military personnel that will incorporate the President's executive order and FDA's interim rule on seeking informed consent waivers. The protocol is expected by early next year.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.